Resource Summary Report

Generated by dkNET on Apr 26, 2025

Coronavirus Immunotherapy Consortium

RRID:SCR_018258
Type: Tool

Proper Citation

Coronavirus Immunotherapy Consortium (RRID:SCR_018258)

Resource Information

URL: https://covic.lji.org/

Proper Citation: Coronavirus Immunotherapy Consortium (RRID:SCR_018258)

Description: Consortium to unite efforts and resources from experts across globe to advance effective, antibody based therapies against novel coronavirus, SARS-CoV-2. Represents multidisciplinary convergence of structural biology, virologists, immunologists, clinicians and bioinformaticians from academic and industry settings. Collects antibodies for testing as part of CoVICS. Contributed antibodies are blinded and will only be known as code name. Antibody contributors will be able to see performance of their own molecules and take part in analysis. Contributors retain ownership of their antibodies and may continue to publish on them using original antibody names. Goal is to determine relative in vitro potency and in vivo efficacy using centralized standardized assays to identify best individual mAbs and rational combinations of mAbs. Consortium will recommend ideal therapeutic molecules for human use to protect vulnerable populations from COVID-19 disease. CoVIC database (CoVIC-DB) will serve as clearinghouse for monoclonal antibodies against SARS-CoV-2. Database will catalog contributed antibodies in searchable resource and provide interactive analysis tools for comparisons among them.

Abbreviations: CoVIC

Resource Type: portal, data or information resource, consortium, organization portal, topical portal

Keywords: COVID-19, antibody, antibody based therapy, coronavirus, SARS-CoV-2, antibody collection, analysis, potency in vitro, efficacy in vivo, standardized assay, identify mAb, therapeutic molecule, vulnerable population protect, database, data

Related Condition: COVID-19

Funding:

Availability: Free, Freely available

Resource Name: Coronavirus Immunotherapy Consortium

Resource ID: SCR_018258

Record Creation Time: 20220129T080339+0000

Record Last Update: 20250426T060705+0000

Ratings and Alerts

No rating or validation information has been found for Coronavirus Immunotherapy Consortium.

No alerts have been found for Coronavirus Immunotherapy Consortium.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET.

Keitany GJ, et al. (2023) Multimodal, broadly neutralizing antibodies against SARS-CoV-2 identified by high-throughput native pairing of BCRs from bulk B cells. Cell chemical biology, 30(11), 1377.

Wayham NP, et al. (2023) A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern. The Journal of infectious diseases, 228(5), 555.

Castro Dopico X, et al. (2022) Immunity to SARS-CoV-2 induced by infection or vaccination. Journal of internal medicine, 291(1), 32.

Yuan TZ, et al. (2022) Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries. mAbs, 14(1), 2002236.

Ferrara F, et al. (2022) A pandemic-enabled comparison of discovery platforms

demonstrates a naïve antibody library can match the best immune-sourced antibodies. Nature communications, 13(1), 462.

Cho H, et al. (2021) Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Science translational medicine, 13(616), eabj5413.

Cho H, et al. (2021) Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants. bioRxiv : the preprint server for biology.

Hastie KM, et al. (2021) Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science (New York, N.Y.), 374(6566), 472.

Arturo EC, et al. (2020) Lifted Up from Lockdown. Cell, 183(1), 1.

DeFrancesco L, et al. (2020) COVID-19 antibodies on trial. Nature biotechnology, 38(11), 1242.